The AChR antibodies are predominantly IgG1 and IgG3 subtypes that bind the complement causing the post-synaptic disorder in NMJ (Sahashi et al., 1980; Vincent and Newsom-Davis, 1980; Tüzün and Christadoss, 2013; Cetin and Vincent, 2018; Howard, 2018); this mechanism is most pathogenic in patients with refractory MG, who have efficaciously been treated with C5 inhibitor (eculizumab and Zilucoplan; Muppidi et al., 2019; Howard et al., 2020). Here, IGHG3 is linked to myasthenia gravis.